Lexaria regains Nasdaq bid price compliance, avoids delisting hearing
Reuters2026/08/17 16:38- Lexaria Bioscience regained Nasdaq compliance with the $1 minimum bid price rule on Aug. 17, 2026.
- Nasdaq cancelled the previously requested hearing; the stock will remain listed on the Nasdaq Capital Market.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Foreign media: XRP holds the $1 mark, but downward pressure remains
OpenAI executives resigning one after another sparks concerns; the president reassures: It's actually normal, we're just under a lot of attention
OpenAI co-founder and president Greg Brockman said on Monday that OpenAI is "under intense scrutiny, so every departure is examined extremely closely," and that these recent personnel changes "are actually not unusual." In recent weeks, three executives have announced their departures: Denise Dresser, head of revenue; Brad Lightcap, executive officer; and Fidji Simo, head of product and business.
Equity Residential amends $2.5 billion revolving credit facility, assumes AvalonBay obligations
Marfrig approves 2Q 2026 quarterly financial report (ITR)
Crypto prices
More
